icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Na´ve or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)....[8 weeks]
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
Fred Poordad1, Franco Felizarta2, Armen Asatryan3, Tarek Hassanein4, Humberto Aguilar5, Jacob Lalezari6, J Scott Overcash7, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Federico J Mensa3, Jens Kort3
1Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Private practi ce, Bakersfi eld, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 5Louisiana Research Center, Shreveport, Louisiana, United States; 6Quest Clinical Research, San Francisco, California, United States; 7eStudySite, San Diego, California, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif